Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Hong

Showing results (121-130 of 442) with videos related to

Pageof 45
Sort By:
JCI Insight|November 21, 2023
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltrationArthur Liu, Seth T Gammon, Federica Pisaneschi, et al.
International Journal of Cancer|September 8, 2016
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTERIshwaria M Subbiah, Jennifer J Wheler, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomesChad Tang, Zhongxing Liao, Daniel Gomez, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 10, 2013
Genomic imprinting effects of the X chromosome on brain morphologyJean-Francois Lepage, David S Hong, Paul K Mazaika, et al.
JAMA Dermatology|April 5, 2013
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenibGerald S Falchook, Peter Rady, Sharon Hymes, et al.
JAMA Network Open|November 25, 2024
Obesity and Outcomes in Adoptive Cellular Therapy in Solid TumorsDerrick L Tao, Mirella Nardo, Cheuk Hong Leung, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II doseWenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Oncotarget|July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitorsIshwaria M Subbiah, Chad Tang, Arvind Rao, et al.
Hepato-Gastroenterology|May 15, 2012
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosisApostolia M Tsimberidou, Siqing Fu, Ishwaria M Subbiah, et al.
Journal of Autism and Developmental Disorders|March 22, 2021
Effects of X Chromosome Monosomy and Genomic Imprinting on Observational Markers of Social Anxiety in Prepubertal Girls with Turner SyndromeScott S Hall, Matthew J Riley, Robyn N Weston, et al.
Pageof 45

Showing results (121-130 of 442) with videos related to

Sort By:
Pageof 45
JCI Insight|November 21, 2023
Hypoxia-activated prodrug and antiangiogenic therapies cooperatively treat pancreatic cancer but elicit immunosuppressive G-MDSC infiltrationArthur Liu, Seth T Gammon, Federica Pisaneschi, et al.
International Journal of Cancer|September 8, 2016
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTERIshwaria M Subbiah, Jennifer J Wheler, Kenneth R Hess, et al.
International Journal of Radiation Oncology, Biology, Physics|July 19, 2014
Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomesChad Tang, Zhongxing Liao, Daniel Gomez, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|May 10, 2013
Genomic imprinting effects of the X chromosome on brain morphologyJean-Francois Lepage, David S Hong, Paul K Mazaika, et al.
JAMA Dermatology|April 5, 2013
Merkel cell polyomavirus and HPV-17 associated with cutaneous squamous cell carcinoma arising in a patient with melanoma treated with the BRAF inhibitor dabrafenibGerald S Falchook, Peter Rady, Sharon Hymes, et al.
JAMA Network Open|November 25, 2024
Obesity and Outcomes in Adoptive Cellular Therapy in Solid TumorsDerrick L Tao, Mirella Nardo, Cheuk Hong Leung, et al.
CPT: Pharmacometrics & Systems Pharmacology|April 5, 2021
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II doseWenyuan Xiong, Manja Friese-Hamim, Andreas Johne, et al.
Oncotarget|July 11, 2018
Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitorsIshwaria M Subbiah, Chad Tang, Arvind Rao, et al.
Hepato-Gastroenterology|May 15, 2012
Intraperitoneal and intravenous chemotherapy in peritoneal carcinomatosisApostolia M Tsimberidou, Siqing Fu, Ishwaria M Subbiah, et al.
Journal of Autism and Developmental Disorders|March 22, 2021
Effects of X Chromosome Monosomy and Genomic Imprinting on Observational Markers of Social Anxiety in Prepubertal Girls with Turner SyndromeScott S Hall, Matthew J Riley, Robyn N Weston, et al.
Pageof 45